APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
